Darzalex CASTOR data shine at ASCO

Data presented at the American Society of Clinical Oncology annual meeting revealed a reduced risk of disease progression and higher response rates among patients treated with Darzalex daratumumab plus Velcade bortezomib and dexamethasone vs. Velcade and dexamethasone alone in the Phase III CASTOR trial to treat relapsed multiple myeloma (MM).

Genmab A/S (CSE:GEN) and its partner, the Janssen unit of Johnson & Johnson (NYSE:JNJ), had said in March that Darzalex met the primary progression-free survival (PFS) endpoint in an interim analysis of CASTOR. J&J stopped the trial early based on an IDMC recommendation (see BioCentury Extra, March 30). ...